ARGX vs REGN: How ARGX and Regeneron Pharmaceuticals Compare (2026)
Last updated July 2026
Short answer
ARGX and REGN are similarly sized, but REGN trades noticeably cheaper on forward earnings (11.62x vs 23.84x): the market is paying up for ARGX's profile and pricing REGN more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
ARGX vs REGN: the tie-breaker metrics
Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ARGX | REGN | What it tells you |
|---|---|---|---|
| Market cap | $54.85B | $65.50B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 23.84 | 11.62 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 38.92 | 15.25 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | -0.02 | 0.24 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 81% of range | 33% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 185.41 | 2.03 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: REGN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how ARGX and REGN affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ARGX and REGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ARGX and REGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does ARGX (ARGX) do?
argenx SE is a Netherlands-based, globally operating immunology company that trades in the US as a Nasdaq ADR. Its lead product, Vyvgart and the subcutaneous Vyvgart Hytrulo (efgartigimod), is an FcRn blocker that lowers pathogenic IgG antibodies. It is approved for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), plus primary immune thrombocytopenia in Japan, and reached roughly 19,000 patients on treatment by the end of 2025.
What does Regeneron Pharmaceuticals (REGN) do?
Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base.
ARGX vs REGN: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ARGX drivers: Vyvgart franchise momentum; Label and indication expansion.
- REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. For REGN, the clearest risk is Eylea biosimilar erosion.
ARGX or REGN: which should you pick?
ARGX vs REGN: the full fundamentals
ARGX. argenx trades as a high-growth, richly valued biotech rather than on trailing earnings multiples, with the roughly $47 billion market cap reflecting expectations for continued Vyvgart expansion and pipeline success. The company is now profitable and self-funding, a meaningful shift from the cash-burning profile common to development-stage biotech. Figures are approximate and reflect data available around May 2026.
REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron reported about 19% revenue growth and adjusted EPS of roughly $9.47 in Q1 2026, beating estimates, and authorized an additional $3 billion buyback. The mid-teens P/E reflects the market weighing strong Dupixent growth against expected Eylea biosimilar erosion.
Headline figures (approximate, May 2026): ARGX shows revenue (2025 product net sales) ~$4.15B, revenue growth (2025 yoy) ~90%, q1 2026 net sales ~$1.3B (+63% YoY), q1 2026 profit ~$366M; REGN shows total revenue (ttm, approx) ~$14 billion, q1 2026 total revenue ~$3.6 billion (up ~19% YoY), dupixent global net sales (q1 2026) ~$4.9 billion (up ~31%), eylea + eylea hd u.s. net sales (q1 2026) ~$941 million combined.
The bottom line: ARGX vs REGN
ARGX and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ARGX and REGN exposure against your real portfolio. It is not an investment adviser.
Build a basket around ARGX with Walnut
Use ARGX as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the difference between ARGX and REGN?
+
argenx SE is a Netherlands-based, globally operating immunology company that trades in the US as a Nasdaq ADR. Regeneron makes money primarily through two large franchises. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ARGX or REGN the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ARGX or REGN?
+
On forward P/E (as of July 2026), ARGX trades at 23.84x and REGN at 11.62x, so REGN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ARGX and REGN?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ARGX vs REGN?
+
ARGX: argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. The FcRn field is crowding: UCB (rozanolixizumab, zilucoplan), Johnson & Johnson (nipocalimab), and Immunovant (batoclimab and IMVT-1402) are all competing in overlapping indications, and AstraZeneca's complement inhibitors address parts of the same market. Pipeline setbacks or missed Phase 3 readouts could sharply reset expectations given the high valuation. As an ADR of a European company, holders also carry currency and cross-listing considerations. Biotech shares like ARGX tend to be volatile around clinical and regulatory events. REGN: The clearest risk is Eylea biosimilar erosion. Amgen's Pavblu launched in late 2024 and pressured sales, and settlements clear paths for Sandoz, and Alvotech and Teva, to launch competing copies in the U.S. around the fourth quarter of 2026, with erosion expected to accelerate. Eylea HD and Dupixent growth are the offsets, but the timing gap matters. The business is also concentrated in a few franchises, so a single setback in Dupixent or a major pipeline failure would weigh heavily, and the collaboration structure with Sanofi means Regeneron does not control all of its largest product's economics.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ARGX or REGN; figures are approximate and dated (as of July 2026). Verify current data before investing.